Skip to main content
Log in

Qi-Long-Tian capsule alleviates pulmonary fibrosis development by modulating inflammatory response and gut microbiota

  • Original Article
  • Published:
Functional & Integrative Genomics Aims and scope Submit manuscript

Abstract

Pulmonary fibrosis (PF) is a chronic, progressive, and fibrotic interstitial lung disease with a high mortality rate. Qi-Long-Tian (QLT) capsule is an herbal formula with great potential for antifibrotic effects, consisting of San Qi (Notoginseng Radix et Rhizoma), Di Long [Pheretima aspergillum (E. Perrier)], and Hong Jingtian (Rhodiolae Crenulatae Radix et Rhizoma), and has been used in clinical practice for many years. To explore the relationship between the effects of Qi-Long-Tian capsule and gut microbiota of PF mice, pulmonary fibrosis model were established by tracheal drip injection of bleomycin. Thirty-six mice were randomly divided into 6 groups: control group (control), model group (model), QLT capsule low dose group (QL), QLT capsule medium dose group (QM), QLT capsule high dose group (QH), and pirfenidone group (PFD). After 21 days of treatment, after pulmonary function tests, the lung tissues, serums, and enterobacterial samples were collected for further analysis. HE staining and Masson’s staining were used to detect changes as the main indicators of PF in each group, and the expression of hydroxyproline (HYP) related to collagen metabolism was detected by and alkaline hydrolysis method. qRT-PCR and ELISA were used to detect the mRNA and protein expressions of pro-inflammatory factors include interleukin 1β (IL-1β), interleukin 6 (IL-6), transforming growth factor β1 (TGF-β1), tumor necrosis factor α (TNF-α) in lung tissues and serums, and the inflammation-mediating factors include tight junction protein (ZO-1, Claudin, Occludin). ELISA was used to detect the protein expressions of secretory immunoglobulin A (sIgA), short-chain fatty acids (SCFAs), and lipopolysaccharide (LPS) in colonic tissues. 16sRNA gene sequencing was used to detect changes in the abundance and diversity of intestinal flora in the control, model, and QM groups, to search for differential genera, and analyze the correlation with inflammatory factors. QLT capsule effectively improved the status of pulmonary fibrosis and reduced HYP. In addition, QLT capsule significantly reduced the abnormal levels of pro-inflammatory factors, including IL-1β, IL-6, TNF-α, and TGF-β in lung tissue and serum, while improving the levels of pro-inflammatory related factors ZO-1, Claudin, Occludin, sIgA, SCFAs, and reducing LPS in the colon. The comparison between the alpha diversity and beta diversity in enterobacteria suggested that the composition of the gut flora in the control, model, and QLT capsule groups were different. QLT capsule significantly increased the relative abundance of Bacteroidia (which might limit the onset of inflammation) and decreased the relative abundance of Clostridia (which might promote inflammation). In addition, these two enterobacteria were closely associated with pro-inflammatory-related indicators and pro-inflammatory factors in PF. All these results suggest that QLT capsule intervenes in pulmonary fibrosis by regulating the differential genera of intestinal flora, increasing immunoglobulin secretion, repairing the intestinal mucosal barrier, reducing LPS entry into the blood, and decreasing inflammatory factor secretion in the serum, which in turn alleviates pulmonary inflammation. This study clarifies the therapeutic mechanism of QLT capsule in PF and provides a theoretical basis for it. It provides a theoretical basis for its further clinical application.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

Similar content being viewed by others

Data availability

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Abbreviations

cAMP:

Cyclic adenosine monophosphate

Cchord:

Quasi-static lung compliance

Claudin:

Tight junction protein

ELISA:

Enzyme linked immunosorbent assay

FEV50/FVC:

50 Ms first expiratory volume/forced vital capacity

FRC:

Functional residual capacity

GM:

Gut microflora

HIV-1:

Human immunodeficiency virus 1

HPLC:

High performance liquid chromatography

HYP:

Hydroxyproline

IL-1β:

Interleukin 1β

IL-6:

Interleukin 6

LPS:

Lipopolysaccharide

MAPK:

Mitogen-activated protein kinase

MMEF:

Mean mid-expiratory flow

Occludin:

Tight junction protein

OTU:

Ovarian tumor domain

PCoA:

Principal coordinate analysis

PEF:

Peak expiratory flow

PF:

Pulmonary fibrosis

PFD:

Pirfenidone

QLT capsule:

Qi-Long-Tian capsule

qRT-PCR:

Real-time fluorescence quantitative PCR

SCFAs:

Short-chain fatty acids

sIgA:

Secretory immunoglobulin A

TGF-β1:

Transforming growth factor β1

TLC:

Total lung capacity

TNF-α:

Tumor necrosis factor α

ZO-1:

Tight junction protein

References

Download references

Acknowledgements

This research was funded by the research on the comprehensive efficacy evaluation of “Tian Long Dao” stage-based treatment program on IPF (The key project of Yunnan Provincial Science and Technology of Chinese Medicine Association) [No. 2017FF117(-007)]. This research was supported by Yunnan Provincial Key Laboratory of Molecular Biology for Sinomedicine, China (No. 2019DG016).

Author information

Authors and Affiliations

Authors

Contributions

Q. Z. and T. L. did the conception and designed of the study. D. -Z. Y. and J. L. drafted the article and revised it critically for important intellectual content. Y. F. and J. -L. Y. approved of the version to be submitted. All authors have read and agreed to the published version of the manuscript.

Corresponding authors

Correspondence to Qiang Zhang or Jiali Yuan.

Ethics declarations

Ethics approval and consent to participate

The animal study protocol was approved by the Animal Care and Welfare Committee of Yunnan University of Chinese Medicine (protocol code: R-06202023, June 15th, 2020).

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 3994 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Q., Luo, T., Yuan, D. et al. Qi-Long-Tian capsule alleviates pulmonary fibrosis development by modulating inflammatory response and gut microbiota. Funct Integr Genomics 23, 64 (2023). https://doi.org/10.1007/s10142-023-00988-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10142-023-00988-3

Keywords

Navigation